Skip to Main content Skip to Navigation
Journal articles

Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients

Abstract : Adoptive therapy for cancer using tumor-infiltrating lymphocytes (TIL) has mainly been investigated in cancer patients with advanced stage disease. The limited clinical success has not been encouraging, although this might be explained by poor TIL specificity and/or high tumor burden. To re-evaluate the effectiveness of adoptive therapy, we analyzed the capacity of tumor-reactive TIL injection in preventing the further development of disease in stage III melanoma patients after complete tumor resection. A phase II/III ran-domized trial was performed on 88 melanoma patients, who received autologous TIL plus interleukin-2 (IL-2) or IL-2 only. The duration of relapse-free survival was analyzed, taking into account the immunological speci-ficity of injected TIL and the number of metastatic lymph nodes removed before treatment. Kaplan-Meyer analysis revealed that the injection of tumor-reactive TIL was statistically correlated with prolonged relapse-free survival in patients with only one metastatic lymph node. Therefore, improved clinical outcome could be obtained after adoptive therapy by selecting appropriate groups of patients and monitoring the specificity of the injected TIL populations.
Complete list of metadata

Cited literature [32 references]  Display  Hide  Download
Contributor : Nathalie LABARRIERE Connect in order to contact the contributor
Submitted on : Monday, February 17, 2020 - 6:44:34 PM
Last modification on : Wednesday, April 27, 2022 - 4:28:28 AM
Long-term archiving on: : Monday, May 18, 2020 - 8:18:16 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




Nathalie Labarrière, Marie-Christine Pandolfino, Nadine Gervois, Amir Khammari, Marie-Helene Tessier, et al.. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunology, Immunotherapy, Springer Verlag, 2002, 51 (10), pp.532-538. ⟨10.1007/s00262-002-0313-3⟩. ⟨inserm-02482115⟩



Record views